Navigation Links
Genaera to Participate in Obesity Panel at RBC Capital Markets Healthcare Conference
Date:12/4/2008

PLYMOUTH MEETING, Pa., Dec. 4 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today announced that Jack Armstrong, President and CEO of Genaera, is scheduled to present at the 2008 RBC Capital Markets Healthcare Conference. The presentation is part of an RBC Capital Markets' panel discussion of obesity, entitled, "Shrinking The Obesity Epidemic," and will take place at the Westin Times Square Hotel in New York on Wednesday, December 11 at 11:00 a.m. ET.

This panel presentation is being webcast at: www.wsw.com/webcast/rbc95/panel6

About Genaera

Genaera Corporation is developing trodusquemine (MSI-1436), for type 2 diabetes and obesity currently in phase 1 clinical testing and has a fully out-licensed partnership with MedImmune, Inc. that is in phase 2 clinical testing in asthma. For further information, please see our website at www.genaera.com.

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to the risks and uncertainties discussed in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at www.sec.gov as well as other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Genaera does not intend (and it is not obligated) to publicly update, revise or correct these forward-looking statements or the risk factors that may relate thereto.


'/>"/>
SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Genaera to Present at Therapeutic Area Partnerships 2008
2. Genaera Receives Non-Compliance Notice From NASDAQ
3. Genaera Corporations 2008 Annual Stockholder Meeting Results
4. Xmark Comments on Genaera Cost-Saving Plan
5. Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph
6. Genaera Corporation Announces Licensing of Exclusive Rights to Pexiganan, a Novel Anti-Infective Drug Candidate, by Macrochem Corporation
7. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
8. ATS Medical to Participate at the RBC Capital Markets Healthcare Conference
9. Individuals Associated with Vinson Hall Retirement Community, Who Survived Pearl Harbor Attack, to Participate in Navy Memorial Event December 7
10. Transcept Pharmaceuticals to Participate on Drug Delivery Investor Panel
11. DURECT Corporation to Participate in Upcoming Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2016)... ... April 30, 2016 , ... Orlando-based Maximized Living has selected Dr. Nick Wilson ... Rio. Under the care of Maximized Living doctors at the London Olympics in ... Maximized Living is sending the largest contingent of elite chiropractors to Rio to support ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... by the Accreditation Council for Graduate Medical Education (ACGME) that it has received ... is the first accreditation of three residency programs that Memorial is currently pursuing, ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Bernie Siegel, ... seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to Death live on ... . Dr. Bernie Siegel, author of a plethora of essential books-to-read for ...
(Date:4/29/2016)... Southlake, Texas (PRWEB) , ... April 29, 2016 , ... ... and neck pain, is proud to announce one of their physicians has been invited ... Osteopathic Family Physicians (Texas ACOFP) Family Practice Review conference on April 30, 2016. ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Melanoma is the deadliest type of skin cancer. ... for the majority of skin cancer deaths. More than 10,000 people are expected to die ... diagnosis is 62, it is the one of the most commonly diagnosed cancers in young ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... April 28, 2016  Marking its one year ... and ovarian cancer risk test, Color Genomics ... genes that highly impact the most common hereditary ... the Color Test analyzes hereditary cancer risks for ... uterine cancers. The Color Test is physician ordered ...
(Date:4/28/2016)... Dr. Vivek Ahuja , ... Ste phen Schmidt ... of cloud-based software solutions for life sciences, today announced key new ... wealth of insight to a growing business.  This will bolster the ... George Phillips joined ArisGlobal in the position of Vice President ...
(Date:4/28/2016)... 2016 New market research ... a report that provides an overview of the ... by identifying new targets and MOAs to produce ... discussed in this H1 2016 Osteoarthritis Pipeline report ... Inc., Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, ...
Breaking Medicine Technology: